about
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Omics Profiling in Precision Oncology.Targeting MET in Lung Cancer: Will Expectations Finally Be MET?Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?Crizotinib targets in glioblastoma stem cells.Detection of MET amplification in gastroesophageal tumor specimens using IQFISH.Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
P2860
Q33679597-7085E75A-965F-4D3E-B9D3-2ABFC37C7383Q33788066-7F9DC3AC-0686-4BD4-8A4A-16FA51290511Q36731336-50CEDE2A-AA79-4A06-ACA6-D7B71AE71BFDQ37051546-3F963B32-7845-40E3-8FF6-9F5AE28EC912Q38385463-D3AD92A8-E878-4B6B-9B1A-EF81F838B6C9Q38675350-DEA55BAE-9016-4E77-95D8-78BDFB3159A9Q38729111-1C65CE92-3A5E-43A8-B05E-6992190B23FCQ38737681-C03A4988-547D-4307-BBEB-384ED4D8E14CQ38813546-D3A132CD-DC2E-4C46-A0F4-D54A8C9C1F87Q38994327-1684DBF8-31D6-40E3-96BD-7298AEAC8997Q43195857-CC1A1763-F449-4AEF-ADBB-A6224B2470D9Q47122191-6C3999AB-F5DB-4A47-89F7-86585D806425Q47171647-FAFF36DF-9DE8-4D6E-9BEC-67AE554DCA57Q53187961-B6523D34-82D7-4F69-B45F-86E743D1D7BEQ53742581-AE7441F5-2357-4194-BF48-193168F6F38CQ55285319-14D32455-D403-4141-8A3F-689310EFDC7CQ55491411-9091B75B-F8C0-4E4A-B256-61C1A30BE353
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Targeting MET Amplification as a New Oncogenic Driver.
@ast
Targeting MET Amplification as a New Oncogenic Driver.
@en
Targeting MET Amplification as a New Oncogenic Driver.
@nl
type
label
Targeting MET Amplification as a New Oncogenic Driver.
@ast
Targeting MET Amplification as a New Oncogenic Driver.
@en
Targeting MET Amplification as a New Oncogenic Driver.
@nl
prefLabel
Targeting MET Amplification as a New Oncogenic Driver.
@ast
Targeting MET Amplification as a New Oncogenic Driver.
@en
Targeting MET Amplification as a New Oncogenic Driver.
@nl
P2093
P2860
P356
P1433
P1476
Targeting MET Amplification as a New Oncogenic Driver
@en
P2093
Isamu Okamoto
Junko Tanizaki
Kazuhiko Nakagawa
Kazuto Nishio
Wataru Okamoto
P2860
P304
P356
10.3390/CANCERS6031540
P577
2014-07-22T00:00:00Z